In patients with obstructive hypertrophic cardiomyopathy, aficamten improved exercise measures, including peak oxygen uptake and recovery, compared to metoprolol, supporting its use as first-line therapy for symptomatic oHCM. ja.ma/4gngler

Exercise Performance With Aficamten vs Metoprolol in oHCM

This randomized clinical trial assesses the use of aficamten vs metoprolol for exercise in patients with obstructive hypertrophic cardiomyopathy.

ja.ma

Increased #Lp(a) levels were associated with higher risk of #CoronaryArteryDisease, but only #IL6 modified Lp(a)-associated CAD risk among UK Biobank participants. ja.ma/4xDn4HW

Lipoprotein(a), Inflammation, and Risk of Coronary Artery Disease and Aortic Valve Stenosis

This cohort study among UK Biobank participants assesses whether inflammatory biomarkers may modify lipoprotein(a)-associated risk for coronary artery disease and aortic stenosis in a primary prevention population.

ja.ma

Supplementation with #Menaquinone7 for 2 years modestly slowed progression of #CoronaryArteryCalcification in patients with coronary artery disease, with no major adverse effects. ja.ma/4hYoxV1

Two Years of Menaquinone-7 Supplementation and Coronary Artery Calcification

This randomized clinical trial evaluates the progression of coronary artery calcification compared with placebo over a 2-year period.

ja.ma

Among adults with Friedreich ataxia cardiomyopathy, intravenous AAVrh.10hFXN gene therapy was well tolerated and associated with increased cardiac frataxin, reduced left ventricular mass index, and lower serum troponin I. ja.ma/4wvCdKr

AAVrh.10hFXN Gene Therapy for the Cardiomyopathy of Friedreich Ataxia

This nonrandomized clinical trial evaluates the safety and preliminary efficacy of administration of AAVrh.10hFXN to adults as gene therapy to treat Friedreich ataxia cardiomyopathy.

ja.ma

💬 Editorial: MK-7 supplementation modestly slowed #CoronaryArteryCalcification progression, but evidence is insufficient regarding clinical benefits or impact on cardiovascular events. ja.ma/4gn1tg1

Coronary Artery Calcium Progression—A Useful Outcome in Clinical Trials?

In this issue of JAMA Cardiology, Vossen et al1 report the results of a randomized clinical trial investigating whether supplementation with the vitamin K homologue menaquinone-7 (MK-7) at a daily dose of 360 µg would delay progression of coronary artery calcification. Among 180 patients with...

ja.ma

💬 Viewpoint: #CardiovascularDisease during #Pregnancy and the postpartum period is becoming more common and more complex, but evidence guiding prevention, diagnosis, and management remains limited. ja.ma/4xd3wuq

This case report discusses intravascular lithotripsy and resultant ventricular fibrillation in a man in his 70s with severely calcified right coronary artery stenosis. ja.ma/4gtjYzE

Among patients with #TransthyretinAmyloidosis with cardiomyopathy, impaired left atrial strain on #Echocardiography was associated with higher risk of death, cardiovascular events, heart failure hospitalization, and atrial fibrillation. ja.ma/4gpsqji

💬 Editorial: At 7 years, #TAVR and #SAVR showed similar rates of structural valve deterioration and failure for low-risk #AorticStenosis, with small annulus predicting higher risk. #NYValves2026 ja.ma/4wz2XtI

Toward a Lifetime Strategy for Aortic Valve Replacement—Ariadne’s Thread

The expansion of transcatheter aortic valve replacement (TAVR) into younger and lower-risk populations has fundamentally reshaped the central question in the management of aortic stenosis (AS).1-3 Procedural safety and early outcomes are no longer the dominant concerns. Instead, the focus has...

ja.ma

💬 Editorial: Prasugrel demonstrated superior efficacy and safety vs clopidogrel and ticagrelor after #PCI for #AcuteCoronarySyndrome, but P2Y12 inhibitor choice must be individualized for patient-specific factors. ja.ma/45xC8Lq

Prasugrel—The Default P2Y12 Inhibitor After PCI for ACS?

Dual antiplatelet therapy remains a mainstay in patients undergoing percutaneous coronary intervention (PCI) after an acute coronary syndrome (ACS), yet selecting the most appropriate P2Y12 inhibitor remains quite challenging.1-3 JAMA Cardiology features a landmark network meta-analysis by Maqsood...

ja.ma

Among patients with Transthyretin amyloid cardiomyopathy, #vutrisiran was associated with favorable changes in cardiac structure, function, and amyloid burden on serial cardiovascular magnetic resonance imaging compared with placebo. ja.ma/4i42ps7

📝 JAMA Cardiology Review: Interatrial dyssynchrony from disease or conventional pacing delays left atrial activation and may raise arrhythmia risk; optimized pacing strategies are an active area of research. ja.ma/4fTlA5i

Among statin-intolerant adults at high cardiovascular risk, #BempedoicAcid was associated with reduced risk of #VenousThromboembolism, including deep vein thrombosis and pulmonary embolism. ja.ma/4fTbd1i

In patients with obstructive #hypertrophic #cardiomyopathy, aficamten improved exercise measures, including peak oxygen uptake and recovery, compared to metoprolol, supporting its use as first-line therapy for symptomatic oHCM. ja.ma/4fLrfvu

Among patients hospitalized with #HeartFailure, both a small left ventricle and a large left ventricle were associated with higher all-cause mortality vs normal size, showing a U-shaped association between left ventricular end-diastolic diameter and risk. ja.ma/4fJDqc9

Both #NonHDLCholesterol and #ApolipoproteinB provided independent, clinically important information for predicting #AtheroscleroticCardiovascularDisease risk, supporting joint assessment of cholesterol content and particle number in risk evaluation. ja.ma/4wORcQX

Among patients hospitalized with #HeartFailure, both a small left ventricle and a large left ventricle were associated with higher all-cause mortality vs normal size, showing a U-shaped association between left ventricular end-diastolic diameter and risk. ja.ma/4z6kE6v

From JAMA: Among patients undergoing elective cardiac surgery, perioperative #dapagliflozin reduced postoperative #AcuteKidneyInjury compared with placebo over 7 days. ja.ma/4wnKyA9

📑 JAMA Cardiology Patient Page: New fatigue, shortness of breath, chest discomfort, dizziness, or leg swelling during or after #BreastCancer treatment may signal #HeartDisease and warrant prompt evaluation. ja.ma/4yLpMwu

📑 JAMA Cardiology Patient Page: New fatigue, shortness of breath, chest discomfort, dizziness, or leg swelling during or after #BreastCancer treatment may signal #HeartDisease and warrant prompt evaluation. ja.ma/4yFtwzP

📑 This case report discusses scimitar syndrome in a woman in her 40s who presented with 8 days of recurrent hemoptysis. ja.ma/4gVK5B0

A 58-year-old woman with a history of mechanical mitral valve replacement presented with progressive exertional dyspnea that had worsened markedly over the preceding 2 weeks. ??What would you do next? ja.ma/4wmsR4w

In patients with #TransthyretinAmyloidCardiomyopathy, acoramidis improved #HeartFailure-related health status vs placebo, with a 9.9-point benefit in Kansas City Cardiomyopathy Questionnaire Overall Summary score at 30 months. ja.ma/3U3v6eF

Among asymptomatic patients with #MitralRegurgitation managed medically, 5-year survival declined from 88% with effective regurgitant orifice area <20 mm2 to 72% with 20-39 mm2 and 55% with >40 mm2. ja.ma/44YzOwH

💬 Viewpoint: #CardioOncology needs to move beyond consensus-driven surveillance toward prospective trials, risk stratification, and clinically meaningful cardiovascular end points in patients with #Cancer. ja.ma/3S1I8J9

📝 JAMA Cardiology Review: Interatrial dyssynchrony from disease or conventional pacing delays left atrial activation and may raise arrhythmia risk; optimized pacing strategies are an active area of research. ja.ma/4puAkf8

Among adults with asymptomatic severe #AorticStenosis, 15% had a positive treadmill stress test, but 20% of these patients remained untreated at 1 year despite AVR indications. ja.ma/4ffwC5J

A digitally enabled quality improvement strategy modestly improved #LDL_C control and increased prescription of combination lipid-lowering therapy for patients with #ASCVD, but many remained above guideline targets. ja.ma/4yxMEiP

The LDL-C–MH-MARS machine learning equation matched the Martin-Hopkins equation for #LDL_C accuracy and outperformed Friedewald, Sampson-NIH, and Modified Sampson equations in nearly 5 million US patients. ja.ma/4hee7Qq

💬 Editorial: Slowed declines in US #IHD mortality are linked to rising obesity and glucose intolerance, contributing to lower life expectancy and healthy years compared with other high-income countries. ja.ma/4wOnawg